ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson

CARY, N.C., Feb. 10, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Stemline Therapeutics Inc., as a limited distribution network specialty pharmacy provider for ORSERDU™ (elacestrant).
Source: McKesson News - Category: Information Technology Source Type: news